vs

Side-by-side financial comparison of Steris (STE) and Vertiv Holdings Co (VRT). Click either name above to swap in a different company.

Vertiv Holdings Co is the larger business by last-quarter revenue ($2.6B vs $1.5B, roughly 1.8× Steris). Vertiv Holdings Co runs the higher net margin — 14.7% vs 12.9%, a 1.8% gap on every dollar of revenue. On growth, Vertiv Holdings Co posted the faster year-over-year revenue change (30.1% vs 9.2%). Vertiv Holdings Co produced more free cash flow last quarter ($652.8M vs $199.5M). Over the past eight quarters, Vertiv Holdings Co's revenue compounded faster (16.5% CAGR vs 15.8%).

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

Vertiv is an American multinational provider of critical infrastructure and services for data centers, communication networks, and commercial and industrial environments.

STE vs VRT — Head-to-Head

Bigger by revenue
VRT
VRT
1.8× larger
VRT
$2.6B
$1.5B
STE
Growing faster (revenue YoY)
VRT
VRT
+21.0% gap
VRT
30.1%
9.2%
STE
Higher net margin
VRT
VRT
1.8% more per $
VRT
14.7%
12.9%
STE
More free cash flow
VRT
VRT
$453.3M more FCF
VRT
$652.8M
$199.5M
STE
Faster 2-yr revenue CAGR
VRT
VRT
Annualised
VRT
16.5%
15.8%
STE

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
STE
STE
VRT
VRT
Revenue
$1.5B
$2.6B
Net Profit
$192.9M
$390.1M
Gross Margin
43.8%
37.7%
Operating Margin
18.3%
Net Margin
12.9%
14.7%
Revenue YoY
9.2%
30.1%
Net Profit YoY
11.2%
EPS (diluted)
$1.96
$0.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STE
STE
VRT
VRT
Q1 26
$2.6B
Q4 25
$1.5B
$2.9B
Q3 25
$1.5B
$2.7B
Q2 25
$1.4B
$2.6B
Q1 25
$1.5B
$2.0B
Q4 24
$1.4B
$2.3B
Q3 24
$1.3B
$2.1B
Q2 24
$1.3B
$2.0B
Net Profit
STE
STE
VRT
VRT
Q1 26
$390.1M
Q4 25
$192.9M
$445.6M
Q3 25
$191.9M
$398.5M
Q2 25
$177.4M
$324.2M
Q1 25
$145.7M
$164.5M
Q4 24
$173.5M
$147.0M
Q3 24
$150.0M
$176.6M
Q2 24
$145.4M
$178.1M
Gross Margin
STE
STE
VRT
VRT
Q1 26
37.7%
Q4 25
43.8%
38.9%
Q3 25
44.2%
37.8%
Q2 25
45.1%
34.0%
Q1 25
43.3%
33.7%
Q4 24
44.5%
37.1%
Q3 24
43.6%
36.5%
Q2 24
44.7%
38.0%
Operating Margin
STE
STE
VRT
VRT
Q1 26
Q4 25
18.3%
20.1%
Q3 25
18.2%
19.3%
Q2 25
17.7%
16.8%
Q1 25
14.6%
14.3%
Q4 24
17.9%
19.5%
Q3 24
16.5%
17.9%
Q2 24
14.5%
17.2%
Net Margin
STE
STE
VRT
VRT
Q1 26
14.7%
Q4 25
12.9%
15.5%
Q3 25
13.1%
14.9%
Q2 25
12.8%
12.3%
Q1 25
9.8%
8.1%
Q4 24
12.7%
6.3%
Q3 24
11.3%
8.5%
Q2 24
11.4%
9.1%
EPS (diluted)
STE
STE
VRT
VRT
Q1 26
$0.99
Q4 25
$1.96
$1.14
Q3 25
$1.94
$1.02
Q2 25
$1.79
$0.83
Q1 25
$1.48
$0.42
Q4 24
$1.75
$0.38
Q3 24
$1.51
$0.46
Q2 24
$1.46
$0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STE
STE
VRT
VRT
Cash + ST InvestmentsLiquidity on hand
$423.7M
$2.5B
Total DebtLower is stronger
$1.9B
$0
Stockholders' EquityBook value
$7.2B
$4.2B
Total Assets
$10.6B
$13.4B
Debt / EquityLower = less leverage
0.27×
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STE
STE
VRT
VRT
Q1 26
$2.5B
Q4 25
$423.7M
$1.7B
Q3 25
$319.2M
$1.4B
Q2 25
$279.7M
$1.6B
Q1 25
$171.7M
$1.5B
Q4 24
$155.2M
$1.2B
Q3 24
$172.2M
$908.7M
Q2 24
$198.3M
$579.7M
Total Debt
STE
STE
VRT
VRT
Q1 26
$0
Q4 25
$1.9B
$2.9B
Q3 25
$1.9B
$2.9B
Q2 25
$1.9B
$2.9B
Q1 25
$1.9B
$2.9B
Q4 24
$2.0B
$2.9B
Q3 24
$2.2B
$2.9B
Q2 24
$2.2B
$2.9B
Stockholders' Equity
STE
STE
VRT
VRT
Q1 26
$4.2B
Q4 25
$7.2B
$3.9B
Q3 25
$7.0B
$3.5B
Q2 25
$7.0B
$3.1B
Q1 25
$6.6B
$2.7B
Q4 24
$6.4B
$2.4B
Q3 24
$6.6B
$1.8B
Q2 24
$6.4B
$1.5B
Total Assets
STE
STE
VRT
VRT
Q1 26
$13.4B
Q4 25
$10.6B
$12.2B
Q3 25
$10.4B
$10.8B
Q2 25
$10.4B
$10.4B
Q1 25
$10.1B
$9.5B
Q4 24
$10.0B
$9.1B
Q3 24
$10.2B
$8.9B
Q2 24
$10.1B
$8.1B
Debt / Equity
STE
STE
VRT
VRT
Q1 26
0.00×
Q4 25
0.27×
0.74×
Q3 25
0.27×
0.83×
Q2 25
0.27×
0.93×
Q1 25
0.29×
1.10×
Q4 24
0.32×
1.20×
Q3 24
0.33×
1.62×
Q2 24
0.35×
1.91×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STE
STE
VRT
VRT
Operating Cash FlowLast quarter
$298.2M
Free Cash FlowOCF − Capex
$199.5M
$652.8M
FCF MarginFCF / Revenue
13.3%
24.6%
Capex IntensityCapex / Revenue
6.6%
4.2%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$917.1M
$2.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STE
STE
VRT
VRT
Q1 26
Q4 25
$298.2M
$978.9M
Q3 25
$287.8M
$508.7M
Q2 25
$420.0M
$322.9M
Q1 25
$260.8M
$303.3M
Q4 24
$332.8M
$425.2M
Q3 24
$250.7M
$378.2M
Q2 24
$303.7M
$378.4M
Free Cash Flow
STE
STE
VRT
VRT
Q1 26
$652.8M
Q4 25
$199.5M
$885.6M
Q3 25
$201.3M
$463.5M
Q2 25
$326.4M
$277.9M
Q1 25
$189.9M
$266.8M
Q4 24
$243.6M
$364.5M
Q3 24
$148.8M
$341.8M
Q2 24
$195.7M
$344.3M
FCF Margin
STE
STE
VRT
VRT
Q1 26
24.6%
Q4 25
13.3%
30.8%
Q3 25
13.8%
17.3%
Q2 25
23.5%
10.5%
Q1 25
12.8%
13.1%
Q4 24
17.8%
15.5%
Q3 24
11.2%
16.5%
Q2 24
15.3%
17.6%
Capex Intensity
STE
STE
VRT
VRT
Q1 26
4.2%
Q4 25
6.6%
3.2%
Q3 25
5.9%
1.7%
Q2 25
6.7%
1.7%
Q1 25
4.8%
1.8%
Q4 24
6.5%
2.6%
Q3 24
7.7%
1.8%
Q2 24
8.4%
1.7%
Cash Conversion
STE
STE
VRT
VRT
Q1 26
Q4 25
1.55×
2.20×
Q3 25
1.50×
1.28×
Q2 25
2.37×
1.00×
Q1 25
1.79×
1.84×
Q4 24
1.92×
2.89×
Q3 24
1.67×
2.14×
Q2 24
2.09×
2.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

VRT
VRT

Segment breakdown not available.

Related Comparisons